NEW YORK ─ Australian microbial genetics firm Microba said on Wednesday that it has inked an agreement with German medical diagnostic services provider Synlab to launch a gut microbiome test, MyBiome, in Europe and Latin America.
The test measures bacterial species in the gut microbiome and calculates their metabolic potential in relation to healthy reference ranges, Microba said.
The product launch will bring its whole-genome metagenomic sequencing and bioinformatics software to new markets, the Brisbane-based company said, and Synlab will make a new gastrointestinal testing service available to its network of doctors and clinics.
Microba's metagenomic analysis platform consists of a sampling technology and next-generation sequencing assay to analyze the genomes of the community of organisms living in the gut.
Microba CEO Blake Wills said in a statement that the product launch will expand the availability of the company’s gut microbiome analysis technology in Europe, a region with unmet demand for microbiome testing services.
Microba and Augsburg, Germany-based Synlab will launch the MyBiome gut microbiome test initially in Spain and Colombia.
In 2019, Microba announced that it had partnered with Macrogen to develop microbiome research services for international markets.